# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Henry Holliday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI007-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Martin Beaumont, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to get back to his dental practice as soon as it is safe for his patients **S**
- He is frightened by the diagnosis and wants to know that it can be cured **S**

## Your goals

- Complete 182 doses of treatment under video-observed therapy within six months. Target: 2026-08-18. Recorded outcome: All 182 doses completed: 56 in the intensive phase and 126 in the continuation phase, with one dose held during a stomach illness and made up at the end. **S**
- Sputum culture negative at two months. Target: 2026-08-18. Recorded outcome: Two-month culture showed no growth, so the continuation phase stayed at four months. **S**
- No alcohol during treatment, to protect his liver. Target: 2026-08-18. Recorded outcome: Not fully met: no drinking for most of the six months, with one evening of heavy drinking at a party about three months into treatment; AUDIT-C 3 at the end. **S**
- Return to work once he is no longer infectious. Target: 2026-03-17. Recorded outcome: Released from home isolation after three negative sputum smears and back at work four weeks into treatment. **S**
- Weight back to at least 64 kg by the end of treatment. Target: 2026-08-18. Recorded outcome: 65.5 kg at the end of treatment, from 58.0 kg at diagnosis. **S**

## What we agreed to do

- Infectious diseases consultation to confirm the regimen and plan monitoring for cavitary pulmonary tuberculosis in a man who drinks heavily. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (2025) **S**
- Standard treatment: isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks, then isoniazid and rifampin for eighteen weeks, by video-observed therapy with the health department, with pyridoxine. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016) **S**
- Monitoring: monthly symptom and weight check, sputum smear and culture monthly until two consecutive cultures are negative, liver tests at two weeks and monthly because of alcohol, and vision checks while on ethambutol. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006) **S**
- Public health: same-day report to the local health department, home isolation until noninfectious, and a contact investigation of his household, coworkers, and patients led by the health department. Guideline: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005) **S**
- Alcohol care: brief intervention at diagnosis, a goal of no alcohol during treatment, counseling with a substance-use counselor, medication offered, AUDIT-C at each visit, and a safety review with the 988 Suicide & Crisis Lifeline at every visit. Guideline: Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024) **S**

## Follow-up

- 2026-02-10: Diagnosis of cavitary pulmonary tuberculosis: sputum, chest X-ray, baseline tests, public-health report, home isolation, and alcohol assessment with a safety assessment **S**
- 2026-02-24: Two-week follow-up on treatment with infectious diseases consultation **S**
- 2026-03-17: Five-week review: susceptibility results, release from isolation, and liver monitoring **S**
- 2026-04-14: End of the intensive phase: two-month sputum and the start of the continuation phase **S**
- 2026-08-18: End-of-treatment review after six months **S**
- 2026-09-22: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
